Discontinued — last reported Q1 '25
Roivant Sciences License, milestone and other revenue — Revenue, net decreased by 100.0% to $0.00 in Q1 2025 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $602.00K to $0.00. Over 2 years (FY 2022 to FY 2024), License, milestone and other revenue — Revenue, net shows an upward trend with a 341.1% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates successful execution of R&D partnerships and the achievement of critical clinical or regulatory hurdles, while a decrease may suggest a lull in partnership activity or failure to meet development targets.
This metric captures non-product revenue streams derived from intellectual property licensing, achievement of clinical o...
Commonly reported by biopharmaceutical companies as 'collaboration revenue' or 'license and milestone revenue,' often fluctuating significantly based on the timing of contract-defined events.
roiv_segment_license_milestone_and_other_revenue_revenue_net| Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $434.75K | $434.75K | $434.75K | $434.75K | $482.00K | $15.03M | $912.00K | $602.00K | $28.78M | $3.85M | $1.21M | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +10.9% | >999% | -93.9% | -34.0% | >999% | -86.6% | -68.5% | -100.0% |
| YoY Change | — | — | — | — | +10.9% | >999% | +109.8% | +38.5% | >999% | -74.4% | +32.9% | -100.0% |